The Successful Retreatment With Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients Who Failed to Respond to NS5A and Protease Inhibitor Treatment

Intern Med. 2019 Apr 1;58(7):943-947. doi: 10.2169/internalmedicine.2077-18. Epub 2018 Dec 18.

Abstract

Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir).

Keywords: HCV; glecaprevir; hemodialysis; pibrentasvir; retreatment.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Retroviral Agents / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Benzimidazoles / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Genotype
  • Hepacivirus / drug effects
  • Hepacivirus / genetics*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Imidazoles / therapeutic use
  • Isoquinolines / therapeutic use
  • Middle Aged
  • Protease Inhibitors / therapeutic use
  • Quinoxalines / therapeutic use*
  • Renal Dialysis*
  • Retreatment / methods
  • Sulfonamides / therapeutic use*
  • Treatment Failure

Substances

  • ABT-493
  • Anti-Retroviral Agents
  • Antiviral Agents
  • Benzimidazoles
  • Imidazoles
  • Isoquinolines
  • Protease Inhibitors
  • Quinoxalines
  • Sulfonamides
  • pibrentasvir
  • daclatasvir
  • asunaprevir